Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7819820 | 0.92 | MAPT (0.56) | MAPTMEN1KMT2ACYP19A1LMNA | |
| SCHEMBL4701157 | 0.89 | MAPT (0.59) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL22117748 | 0.88 | MAPT (0.61) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL31071652 | 0.88 | MAPT (0.61) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL29227165 | 0.86 | CYP19A1 (0.56) | MAPTMEN1KMT2ACYP19A1LMNA | |
| SCHEMBL29227222 | 0.86 | CCR5 (0.57) | MAPTMEN1KMT2ACYP19A1LMNA | |
| SCHEMBL6987550 | 0.86 | CYP19A1 (0.59) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL6927459 | 0.86 | CYP19A1 (0.57) | MAPTMEN1KMT2ACYP19A1LMNA | |
| SCHEMBL4342277 | 0.86 | MAOA (0.48) | MAPTMEN1KMT2ACYP19A1LMNA | |
| SCHEMBL8676608 | 0.85 | MEN1 (0.62) | MAPTMEN1KMT2ACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| CN-1321153-A | telomerase inhibitors and methods of use thereof | GERON CORP (US) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | MAPT 3329/4885MEN1 2982/4885KMT2A 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.